Observational studyOncotarget2017

A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma.

Min Kyoung Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.